BridgeBio Pharma, Inc. (BBIO) Form 10-Q — Oct 29, 2026
BridgeBio Pharma's Q3 2026 revenue nearly tripled to $353.2 million from $120.7 million a year ago, powered by the U.S.
Key figures
- Revenue
- 353171000
- Revenue Yoy
- Q3 total revenues +192.6% ($353.2M vs $120.7M); nine-month revenues $791.4M vs $347.9M
- Total Assets
- 2161786000
- Cash Position
- 1533363000
- Shares Outstanding
- 194800782
- Pdufa dates
- ["BBP-418: Nov 27, 2026","encaleret: May 8, 2027","infigratinib: Feb 4, 2027"]
- Total debt face
- $2.505B convertible notes face value (2027 $550M, 2029 $747.5M, 2031 $575M, 2033 $632.5M)
- Q3 2025 total revenue
- 120700000
- Preferred stock issued
- 933,900 shares Series A at 7.00% initial dividend rate, $1,134.4M liquidation preference
- Q3 net product revenue
- 253346000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.